General Information of Drug (ID: DMHBZ0N)

Drug Name
PMID23639540C13r Drug Info
Synonyms GTPL8144; BDBM50434750
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
60182364
TTD Drug ID
DMHBZ0N

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Preclinical Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
INCB00928 DMFG8TI Anemia 3A00-3A9Z Phase 2 [2]
TP-0184 DMJVZBC Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
PMID27774822-Compound-Figure10Compound12 DMFAGOZ N. A. N. A. Patented [4]
PMID27774822-Compound-Figure10Compound4 DMMJVTW N. A. N. A. Patented [4]
PMID23639540C13d DMSTQGH Discovery agent N.A. Investigative [1]
PMID23639540C13a DMLXOAQ Discovery agent N.A. Investigative [1]
LDN-214117 DM57Z8J Discovery agent N.A. Investigative [5]
ML347 DMR8N36 Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 8 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-03446962 DMTJWNE Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
PMID23639540C13d DMSTQGH Discovery agent N.A. Investigative [1]
PMID23639540C13a DMLXOAQ Discovery agent N.A. Investigative [1]
LDN-214117 DM57Z8J Discovery agent N.A. Investigative [5]
ML347 DMR8N36 Discovery agent N.A. Investigative [1]
Drug Name Drug ID Indication ICD 11 Highest Status REF
US9682983, 1 DM6EQVT N. A. N. A. Patented [7]
BDBM108945 DMZD6IJ N. A. N. A. Patented [7]
US10030004, Compound 19 DM0RAPC N. A. N. A. Patented [8]
US9682983, 33 DM6R1YP N. A. N. A. Patented [7]
US10030004, Compound 33 DMD0GN6 N. A. N. A. Patented [8]
US10030004, Compound 11a DMG4T13 N. A. N. A. Patented [8]
PMID23639540C13d DMSTQGH Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 7 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY2157299 DMP8HW1 Arteriosclerosis BD40 Phase 2/3 [9]
TEW-7197 DM2LBC3 Myeloproliferative neoplasm 2A20 Phase 2 [10]
Metelimumab DMENFD6 Scleroderma 4A42 Phase 1/2 [11]
TP-0184 DMJVZBC Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
P-2745 DMJ3PNS Chronic myelogenous leukaemia 2A20.0 Phase 1 [12]
LY3200882 DMQP6VB Solid tumour/cancer 2A00-2F9Z Phase 1 [13]
PF-06952229 DMDQJEZ Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
SB-431542 DM0YOXQ Pulmonary fibrosis CB03.4 Preclinical [15]
SM-16 DMHXJV2 Fibrosis GA14-GC01 Terminated [16]
LF-984 DMIYMS2 Fibrosis GA14-GC01 Terminated [17]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID23639540C13d DMSTQGH Discovery agent N.A. Investigative [1]
PMID23639540C13a DMLXOAQ Discovery agent N.A. Investigative [1]
LDN-214117 DM57Z8J Discovery agent N.A. Investigative [5]
ML347 DMR8N36 Discovery agent N.A. Investigative [1]
AA-184 DMCN4ZD Kidney injury NB92.0 Investigative [18]
AA-204 DMBGTX9 Kidney disease GC2Z Investigative [18]
AA-123 DMW73A8 Prostate cancer 2C82.0 Investigative [18]
AA-166 DM2BMAZ Articular cartilage disorder FA34.Y Investigative [18]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Activin receptor type IB (ACVR1B) TTPKHTZ ACV1B_HUMAN Inhibitor [1]
Activin receptor-like kinase 2 (ALK-2) TTJNBQA ACVR1_HUMAN Inhibitor [1]
Activin receptor-like kinase-1 (ACVRL1) TTGYPTC ACVL1_HUMAN Inhibitor [1]
Bone morphogenetic protein receptor (BMPR2) TTGKF90 BMPR2_HUMAN Inhibitor [1]
TGF-beta receptor type I (TGFBR1) TTP4520 TGFR1_HUMAN Inhibitor [1]

References

1 Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
2 Clinical pipeline report, company report or official report of Incyte.
3 Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
4 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
5 Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15.
6 ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. 2011 June 30; 117(26): 6999-7006.
7 BMP inhibitors and methods of use thereof. US9682983.
8 Compounds and methods of use. US10030004.
9 Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol. 2015 Oct;15(4):309-23.
10 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
11 Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004 Dec;3(12):1011-22.
12 Novel potent inhibitor of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines. Cancer Research. 06/2012; 72(8 Supplement):1822-1822.
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 Targeting the TGF pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31.
15 Pyrazolone based TGFbetaR1 kinase inhibitors. Bioorg Med Chem Lett. 2010 Jan 1;20(1):326-9.
16 TGF-beta type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody. Int Immunol. 2007 Feb;19(2):117-26.
17 US patent application no. 2013,0028,978, Compositions and methods for wound treatment.
18 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1794).